Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
23:31:10 EDT Fri 26 Apr 2024
Enter Symbol
or Name
USA
CA



Q:NKTX - NKARTA INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
NKTX - Q0.16.88·7.590.16.87+0.050.7978.36,1776,7796.83  7.14  6.5216.24  1.2819:45:42Apr 0315 min RT 2¢

Recent Trades - Last 10 of 6779
Time ETExPriceChangeVolume
19:45:42Q6.880.061
18:16:15Q6.990.172
17:16:00Q7.000.1870
16:43:26Q7.000.182
16:20:00Q6.870.05242
16:13:44Q6.870.0511
16:01:46Q6.870.05720
16:00:11Q6.870.051,368
16:00:11Q6.870.05928
16:00:02Q6.870.05242

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-03 16:02U:NKTXNews ReleaseNkarta to Participate in Upcoming Investor Conferences
2024-03-25 06:30U:NKTXNews ReleaseNkarta Announces Pricing of $240 Million Underwritten Offering
2024-03-21 16:01U:NKTXNews ReleaseNkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
2024-02-28 08:01U:NKTXNews ReleaseNkarta to Participate in Upcoming Investor Conferences
2024-01-09 10:25U:NKTXNews ReleaseGlobal Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030
2023-12-09 20:31U:NKTXNews ReleaseNkarta Presents NKX101 Clinical Data at the 2023 American Society of Hematology Annual Meeting & Exposition
2023-11-09 16:02U:NKTXNews ReleaseNkarta Reports Third Quarter 2023 Financial Results and Corporate Highlights
2023-11-07 08:02U:NKTXNews ReleaseNkarta to Participate at Upcoming Investor Conferences
2023-10-17 11:47U:NKTXNews ReleaseLupus Therapeutics Announces Partnership to Support the Evaluation of Natural Killer (NK) Cell Therapy in Lupus Nephritis
2023-10-17 07:01U:NKTXNews ReleaseNkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis
2023-10-16 16:01U:NKTXNews ReleaseNkarta to Host Conference Call on Tuesday, October 17 at 8am ET to Discuss Expansion of Clinical Pipeline and Organizational Cost Measures
2023-08-10 07:01U:NKTXNews ReleaseNkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights
2023-08-03 08:02U:NKTXNews ReleaseNkarta to Participate at Upcoming Investor Conference
2023-07-05 16:02U:NKTXNews ReleaseNkarta Appoints Alyssa Levin Chief Financial and Business Officer
2023-06-27 07:01U:NKTXNews ReleaseNkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia
2023-06-26 16:01U:NKTXNews ReleaseNkarta to Host Conference Call to Discuss Updated Clinical Data from NKX101 NK Cell Therapy Program
2023-06-10 10:48U:NKTXNews ReleaseNkarta Presents NKX019 Clinical Data at the European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma
2023-05-11 16:02U:NKTXNews ReleaseNkarta Reports First Quarter 2023 Financial Results and Corporate Highlights
2023-05-11 16:01U:NKTXNews ReleaseNkarta to Present NKX019 Phase 1 Dose Escalation Data at European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma